For people with type 1 diabetes, management burden including suboptimal insulin preparations remains a major barrier to ...
Insulin efsitora was able to lower A1C in patients with type 1 diabetes but more patients experienced severe hypoglycemic ...
Combination may offer a substitute to basal-bolus insulin in people with type 2 diabetes inadequately controlled with daily basal insulin.
"EASD 2024: A COMBINEd approach for better diabetes management" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.
Shortly after a positive data drop for Eli Lilly’s efsitora a | Lilly revealed that its weekly insulin candidate efsitora ...
Eli Lilly’s experimental insulin that is injected just once a week is as effective as daily insulin injections for ...
The late-stage clinical trial results showed that Eli Lilly’s once-weekly insulin efsitora matched daily injections for ...
Eli Lilly's efsitora alfa was noninferior to once-daily insulin in type 2 diabetes, but an increased hypoglycemia risk was seen in type 1 diabetes.
The latest clinical trial results from Eli Lilly show the drug manufacturer's once-weekly insulin injection is just as ...
An investigational once-weekly insulin was noninferior to a daily option for patients with type 2 diabetes, but proved risky ...
New research published in New England Journal of Medicine and presented at this year's Annual Meeting of the European ...
If you've recently received a diagnosis of type 2 diabetes, understanding your treatment options is an important first step.